Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5361 - 5368 of 12092 results
Judge Dismisses FCA Claims Against Compounding Pharmacy and Private Equity Firm Owner but Allows the Government to Amend
March 13, 2019| Blog| Viewpoint
Processing Delays Reveal USCIS Stretched To Its Limits
March 13, 2019| News
Where in the World Is the Gig Economy Working?
March 12, 2019| News
DOJ Antitrust Division Makes Filings in Civil Cases to Influence Development of Antitrust “No Poach” Law
March 12, 2019| Alert| Viewpoint
Designing Around a Monopoly: the Public Interest Dispute between Qualcomm and Apple Takes a New Turn
March 12, 2019| Blog| Viewpoint
USCIS Resumes Premium Processing Today for ALL H-1B Petitions
March 12, 2019| Alert| Viewpoint
Teva Putative Federal Securities Class Member Seeks to Toll Statute of Repose with Motion to Intervene
March 12, 2019| Blog| Viewpoint
Mintz Bulks Up High-Growth Corporate Practice With Boston Duo
March 12, 2019| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|